Overview

• Biopharmaceutical firm's Q4 2025 revenue rose 11%, slightly beating analyst expectations

• Adjusted EPS for Q4 2025 beat analyst expectations

• Specialty segment revenue increased 38%, driven by CREXONT and UNITHROID

Outlook

• Amneal forecasts 2026 net revenue between $3.05 bln and $3.15 bln

• Company expects 2026 adjusted EBITDA of $720 mln to $760 mln

• Amneal anticipates 2026 adjusted diluted EPS of $0.93 to $1.03

Result Drivers

• SPECIALTY SEGMENT - Specialty net revenue increased 38% driven by strong uptake of CREXONT and UNITHROID

• AFFORDABLE MEDICINES - Affordable Medicines net revenue decreased 1% due to timing of revenue for key products and new launches

• AVKARE GROWTH - AvKARE net revenue increased 24% driven by growth in the government label sales channel

Company press release: ID:nGNX7PW6Sw

Key Details

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Amneal Pharmaceuticals Inc is $15.00, about 3.5% above its February 26 closing price of $14.49

• The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 12 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.